HR. 1492In Committee
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Lengthens the Medicare Drug Price Negotiation Program approval period for small-molecule drugs to match biologics and applies the change retroactively
Plain-English overview
What this bill does
Lengthens the Medicare Drug Price Negotiation Program approval period for small-molecule drugs to match biologics and applies the change retroactively
Key points
- Amend drug eligibility timeline
- Require 11 years approval
- Extend retroactive application
Current status
Where it stands
Status
In Committee
Latest action
2025-02-21 — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Related context
Topics and policy areas
undefinedHealthHealth care costs and insuranceMedicarePrescription drugs